#delta-9-thc — Public Fediverse posts

https://www.europesays.com/it/619413/ Un farmaco al THC può spegnere gli incubi del PTSD? #Delta9THC #DisturboDaStressPostTraumatico #dronabinol #EurekAlert #Health #incubi #IT #Italia #Italy #NatureMedicine #PTSD #rem #Salute #SistemaEndocannabinoide #thc

Ohio’s Hemp Ban Hits a Wall in Court

Filed Under: Market Protection Politics

Ohio tried to lock down the hemp market.
The law moved fast. The court moved faster.
Now the state is being forced to defend whether this was about safety or control.

“This is thus inherently discriminatory on its face.”
— Jeremiah S. Ray, in granting a temporary restraining order

On April 8, 2026, the court blocked enforcement of the hemp-related provisions less than three weeks after the law took effect.

The fight is not about THC. It’s about who gets to sell it.

Senate Bill 56 took effect on March 20, 2026, and with it, Ohio attempted to redraw the boundaries of its cannabis economy. The law revised both marijuana and hemp policy in a way that targeted a fast-growing category lawmakers had largely ignored until it became impossible to ignore.

Intoxicating hemp.

For years, hemp lived in a narrow legal definition. Low THC, industrial use, tightly capped. That changed after the 2018 federal Farm Bill legalized hemp and defined it based on delta-9 THC concentration. What followed was not gradual. It moved fast.

Manufacturers began producing hemp-derived cannabinoids like delta-8, delta-10, and other compounds that could deliver psychoactive effects while technically remaining within the federal definition of hemp. These products moved quickly into the market. Gummies, vapes, beverages, tinctures. They showed up everywhere the traditional cannabis system did not reach.

Smoke shops. Gas stations. Bars. Boutique retailers. Online storefronts.

No dispensary license required.

Ohio watched that market grow in real time.

Senate Bill 56 was the response.

Lawmakers framed it as a necessary correction to a system that had drifted too far without oversight. The concern, as presented publicly, centered on safety. Products that were intoxicating but not subject to the same testing, labeling, and distribution controls as state-licensed marijuana. Items that could be accessed more easily by underage consumers. A category that regulators could not fully track.

Lawmakers’ “primary concern with intoxicating hemp” was unregulated products, especially edibles, where “we don’t know where it came from.”
— Rob McColley

That argument isn’t baseless. The hemp market did not develop under the same regulatory guardrails as state marijuana programs. It moved faster than policy, and in many cases, faster than oversight.

But Senate Bill 56 did not just impose safety standards.

It restructured the market.

At its core, the law limits how and where intoxicating hemp products can be sold. It narrows distribution channels. It places restrictions on products that had been widely available in general retail environments. And in doing so, it creates a divide between two forms of THC commerce that now operate under entirely different expectations.

On one side, hemp-derived THC is federally legal, but now constrained at the state level.

On the other hand, marijuana is federally illegal, but protected within Ohio’s licensed dispensary system.

That contradiction is built into the structure of the law.

Hemp businesses argue that Senate Bill 56 effectively removes them from the market they helped build. Companies that invested in hemp beverages, edibles, and alternative cannabinoid products now face a landscape where their products are restricted or pushed into systems designed for licensed marijuana operators.

For small retailers, the shift is immediate.

A bar that once carried THC-infused beverages may no longer be able to sell them. A smoke shop that stocked delta-8 products as a core revenue stream now faces compliance pressure or removal. Distributors that built supply chains around hemp products risk losing access to the state altogether.

For manufacturers, the risk is larger.

Production lines built around hemp-derived cannabinoids are not easily converted to fit within a marijuana licensing framework. The cost, the regulation, the access barriers. These are not minor adjustments. They are structural obstacles that many businesses cannot absorb.

The field narrows.

Fewer sellers. Fewer access points. More control is concentrated within the licensed system.

That is where the legal challenge begins.

advertisement

F O R T H E C U L T U R E B Y T H E C U L T U R E

THE MONEY BEHIND CANNABIS PROHIBITION

Cannabis prohibition in the United States no longer survives on raids and panic films. It survives through ballot thresholds, legislative rewrites, regulatory choke points, and lobbying disclosures. This documented audit follows the filings behind legalization war chests, opposition strategies, and the institutional structures that still shape cannabis policy even after voters move on.

OHIO’S LEGALIZATION FIGHT IS ABOUT CONTROL, NOT CANNABIS

Ohio voters approved adult use cannabis with 57 percent support in 2023. Two years later, lawmakers narrowed that framework through Senate Bill 56. A referendum campaign now seeks to overturn those revisions, requiring roughly 248,000 valid signatures statewide. This piece breaks down what changed, who changed it, and what voters are being asked to decide…

Ohio Tightens Screws On Legal Weed

Ohio voters approved legalization, but lawmakers followed with Senate Bill 56, a measure that tightens control through enforcement expansion, licensing caps, and market restrictions. This piece breaks down what the law actually changes, who benefits from the new structure, and how state authority grows while legal access narrows after the vote.

advertisement

On April 8, 2026, Judge Jeremiah S. Ray issued a temporary restraining order blocking enforcement of the hemp-related portion of Senate Bill 56 in Fremont. The ruling does not decide the case, but it signals that the legal foundation of the law may not hold.

The issue is not simply regulation. It is discrimination.

Under the Commerce Clause, states are limited in how they regulate markets that cross state lines. They cannot pass laws that unfairly burden or discriminate against certain categories of commerce without sufficient justification.

That matters here because hemp exists within interstate commerce. It is federally legal, produced and distributed across state lines, and sold through ordinary retail channels.

A constitutional law professor at Case Western Reserve University, cited in coverage of the ruling, noted that states cannot pass laws that interfere with or discriminate against interstate commerce. If a law creates an uneven playing field without a defensible basis, it becomes vulnerable.

Senate Bill 56 appears to do exactly that.

It restricts one form of THC commerce while preserving another.

It limits products that are federally legal while maintaining access to products that are federally prohibited but state-sanctioned.

That tension doesn’t hold cleanly.

The state’s defense remains rooted in safety. Lawmakers argue that intoxicating hemp products operate in a space with inconsistent standards, unclear sourcing, and insufficient protections, particularly for younger consumers.

Those concerns are real, and they have been echoed in multiple states dealing with similar markets.

But the court’s early assessment suggests the law may go further than addressing those risks.

If the structure of the law disproportionately burdens federally legal hemp while leaving state-licensed marijuana intact, the justification must hold under constitutional scrutiny. It is not enough to claim risk. The approach must be consistent, non-discriminatory, and grounded in a legitimate regulatory purpose.

That is a high bar.

Because once a state begins separating identical consumer effects based on licensing instead of substance, it risks drawing a legal distinction that courts are more willing to question. If two products deliver similar outcomes but are treated differently based on origin or distribution channel, the burden shifts back to the state to explain why that difference exists and whether it holds up under constitutional scrutiny.

Because the law does not eliminate THC.

It channels it.

If a consumer cannot purchase a hemp-derived THC product at a retail shop, but can purchase a marijuana product through a licensed dispensary, the issue is not access to THC. It is access to who is allowed to sell it.

That distinction is critical.

And it is not unique to Ohio.

Across the country, states are grappling with the same problem. Hemp markets expanded under federal law, often outpacing state-level regulation. Once those markets reached scale, states began moving to restrict, absorb, or eliminate them.

Some have imposed outright bans on certain cannabinoids. Others have moved to bring hemp products under the same regulatory umbrella as marijuana. In many cases, the justification is the same. Safety. Consistency. Control.

But the effect is often similar.

A shift in who controls the market.

Ohio may now be one of the first places where that strategy faces direct constitutional scrutiny.

The speed matters.

Senate Bill 56 took effect on March 20. By April 8, a court had already intervened.

Not typical. That’s friction.

And it suggests that the legal questions raised by the law are not minor.

For cannabis culture, the implications go beyond compliance and regulation.

The divide between hemp and marijuana is no longer just legal. It is cultural and economic.

One side is absorbed into a system that is licensed, taxed, and protected. It is framed as legitimate, controlled, and acceptable.

The other side, built on a different legal pathway but serving a similar demand, is treated as unstable and expendable.

That split reflects a shift from prohibition to control, where the question is no longer whether cannabis exists in the market, but who is allowed to participate in it.

Ohio did not try to eliminate THC.

It tried to decide who gets to sell it.

Now that decision is being tested in court.

And for the first time since Senate Bill 56 took effect, the outcome is not entirely in the state’s control.

©2026 Pot Culture Magazine. All rights reserved. This content is the exclusive property of Pot Culture Magazine. It may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission from the publisher, except for brief quotations in critical reviews.

F O R T H E C U L T U R E B Y T H E C U L T U R E

CANNABIS LIES Vol. 8: The Addiction Lie

Cannabis is often labeled addictive, but the science tells a more precise story. This piece breaks down cannabis use disorder, how it is defined, and why mild, moderate, and severe cases get flattened into one fear-driven narrative. The result is a distorted public understanding of risk that fuels policy, perception, and misinformation.

Australia Cracks Down on Medical Cannabis

Australia’s medical cannabis system expanded rapidly through telehealth and high-volume prescribing. Now regulators are tightening oversight. The TGA and AHPRA are increasing scrutiny on prescribing practices, signaling a shift from rapid patient access toward stricter clinical control that could reshape how doctors prescribe and how patients obtain treatment.

Missouri Tightens Grip On Hemp Sales

Missouri legalized cannabis, then moved to squeeze intoxicating hemp into the dispensary system. HB 2641 is being sold as consumer protection, but critics say it protects licensed marijuana operators while threatening hemp retailers, growers, and small businesses across the state.

Cannabis medicinal ayuda a tratar epilepsia

Alternativa terapéutica en México crece

Por Deyanira Vázquez | Reportera                                        

La epilepsia afectó a 70 millones de personas en el mundo, según la Organización Mundial de la Salud. Esta condición neurológica, caracterizada por convulsiones recurrentes, generó retos médicos y sociales importantes. En países de ingresos bajos y medios, el acceso a tratamiento fue limitado.

En México, cerca de dos millones de personas vivieron con epilepsia, según el sitio oficial del gobierno federal. Especialistas en neurología clínica precisaron que los síntomas aparecen sobre todo en la infancia. También se presentó con mayor frecuencia en personas mayores de 60 años.

Uso terapéutico del cannabis

El interés por el cannabis medicinal aumentó en el tratamiento de padecimientos neurológicos como la epilepsia. La planta contiene más de cien compuestos terpenofenólicos llamados cannabinoides. Los más estudiados han sido el tetrahidrocannabinol (THC) y el cannabidiol (CBD).

Modelos preclínicos mostraron que los cannabinoides poseyeron efectos anticonvulsivos. Desde entonces, se utilizaron extractos con CBD y cannabidiol purificado en pacientes. Estos tratamientos se aplicaron con respaldo de estudios abiertos y ensayos clínicos aleatorizados.

Extractos frente a CBD puro

Un artículo de la revista Neurología, editada por Elsevier, detalló dos productos principales para epilepsia refractaria. Estos fueron el cannabidiol al 100% y extractos enriquecidos con CBD. Ambos ofrecieron resultados favorables en pacientes resistentes a tratamientos convencionales.

Aunque comparten principio activo, no se consideraron equivalentes ni intercambiables. El CBD purificado es un compuesto aislado, mientras que los extractos contienen más elementos. Estos componentes interactuaron entre sí y modificaron el efecto terapéutico del medicamento.

Sinergia botánica y evidencia

El estudio explicó que los extractos enriquecidos representan un modelo de sinergia botánica. Este fenómeno multiplica el beneficio terapéutico por la acción conjunta de compuestos naturales. Por ello, se recomendó evaluar eficacia y seguridad de manera diferenciada entre ambos formatos.

El médico bariatra David Montalvo, especialista en medicina cannábica, expuso que el extracto de espectro completo ofreció mejores resultados. Este producto incluye diversos ingredientes naturales llamados terpenos, responsables del olor y color de la planta.

Efectos terapéuticos de terpenos

Los terpenos brindaron a la planta protección frente a radiación solar e insectos. En el cuerpo humano, sus efectos terapéuticos abarcaron desde propiedades antibacterianas hasta funciones anticonvulsivas. También actuaron como relajantes musculares, sedantes y broncodilatadores.

Se observaron efectos analgésicos, ansiolíticos y antidepresivos según la combinación con otros cannabinoides. El uso controlado de estas sustancias mejoró el abordaje clínico de epilepsias de difícil control. Los estudios respaldaron el uso de extractos completos sobre aislados.

CBD y THC en proporción segura

El ingrediente que potenció el efecto del CBD fue el Delta-9-THC, en dosis mínimas. El especialista explicó que se requería una proporción CBD-THC de 20 a 1. Esta cantidad fue segura y no generó efectos psicotrópicos adversos en los pacientes.

La combinación de ambos cannabinoides permitió una mejor modulación de las crisis convulsivas. La supervisión médica garantizó que los efectos terapéuticos fueran favorables y sostenidos en el tiempo.

Dosificación y vía de administración

La forma de administración más recomendada fue en gotas sublinguales. Esta vía permitió una absorción rápida y controlada del medicamento. Además, facilitó el ajuste progresivo de la dosis según el paciente.

El tratamiento inició con dosis bajas y se ajustó según respuesta clínica. La concentración inicial de CBD fue de entre 5 y 10 mg. Esta cantidad varió dependiendo del peso, edad y gravedad de las convulsiones.

Casos de evolución prolongada

En pacientes con epilepsia de larga evolución, la dosis aumentó hasta 20 mg diarios. El ajuste individualizado fue clave para evitar efectos secundarios. La supervisión profesional acompañó cada etapa del tratamiento.

El médico David Montalvo aclaró que la personalización del tratamiento fue indispensable. Esto permitió alcanzar el efecto terapéutico con la menor cantidad posible del producto.

Acceso, investigación y regulación

El uso del cannabis medicinal con fines terapéuticos avanzó en México. Sin embargo, aún existieron desafíos legales, regulatorios y sociales para garantizar su acceso. La epilepsia fue una de las condiciones con más evidencia científica a favor de su uso.

El respaldo de ensayos clínicos fortaleció la legitimidad del CBD en epilepsias de difícil control. En consecuencia, más familias accedieron a estas opciones bajo supervisión médica. –sn–

¡Conéctate con Sociedad Noticias! Suscríbete a nuestro canal de YouTube y activa las notificaciones, o bien, síguenos en las redes sociales: Facebook, Twitter e Instagram.

También, te invitamos a que te sumes a nuestro canal de información en tiempo real a través de Telegram.

#cannabidiolEnNiños #cannabisMedicinalEpilepsia #cannabisTerapéuticoMéxico #CBDSublingual #Cdmx #DavidMontalvo #Delta9THC #efectosDelCBD #epilepsiaAdultosMayores #epilepsiaInfantil #epilepsiaMéxico #epilepsiaOMS #epilepsiaRefractariaTratamiento #epilepsiaTratamientoAlternativo #espectroCompletoCannabis #extractoFullSpectrum #gotasCBDEpilepsia #Información #InformaciónMéxico #México #medicinaCannábicaMéxico #Morena #noticia #noticias #NoticiasMéxico #NoticiasSociedad #saludNeurológicaMéxico #SN #Sociedad #SociedadNoticias #SociedadNoticiasCom #sociedadNoticias #SociedadNoticiasCom #terpenosEpilepsia #tratamientoCBDEpilepsia